Therefore, when considering the bimodal expression of ER in female breast cancers, it is reasonable that all female patients indicated to undergo 21-gene expression assay testing are strongly ER-positive, which explains the comparable results for female and MBC patients undergoing 21-gene expression assay testing. This evidence concerns the gene ESR1 and breast carcinoma.